September 1, 1998Cardiovascular ResearchOpen Access

Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

TRTon J. RabelinkLeiden University Medical Center

Discussion

Member takes

Implication

Endothelin receptor blockers merit further preclinical renal protection studies; leaves open clinical translation pending toxicity resolution.

Structured PICO

Intervention

Endothelin receptor blockers (ETA selective and mixed ETA/ETB antagonists) and endothelin converting enzyme (ECE) inhibitors

Endothelin receptor blockers hold potential for preventing end-organ renal damage in cardiovascular disease, hypertension, and diabetes, though clinical use is currently limited by significant toxicity.

Limitations

Toxicity of endothelin receptor blockers including headaches and liver toxicity
Teratogenicity limits application in women of child-bearing potential

Cite This Study

Ton J. Rabelink (1998) studied this question.

synapsesocial.com/papers/6a7247c535aa2c282ce32cc6 https://doi.org/10.1016/s0008-6363(98)00155-2

View Full Paper

Ask AI

Bookmark

Implication

Endothelin receptor blockers merit further preclinical renal protection studies; leaves open clinical translation pending toxicity resolution.

Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider